Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24

About Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24

Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 + Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 is a phase 3 stage product being developed by Ocular Therapeutix for Non-Proliferative Diabetic Retinopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07235085. Target conditions include Non-Proliferative Diabetic Retinopathy.

What happened to similar drugs?

0 of 1 similar drugs in Non-Proliferative Diabetic Retinopathy were approved

Hype Score Breakdown